UNITY Biotechnology Inc.

08/12/2022 | Press release | Distributed by Public on 08/12/2022 05:19

UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema - Form 8-K